Marker Therapeutics, Inc. (MRKR) Insider Trading Activity

NASDAQ$1.18
Market Cap
$19.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
670 of 853
Rank in Industry
384 of 492

MRKR Insider Trading Activity

MRKR Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Insider Activity of Marker Therapeutics, Inc.

Over the last 12 months, insiders at Marker Therapeutics, Inc. have bought $0 and sold $0 worth of Marker Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Marker Therapeutics, Inc. have bought $1.81M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 554,250 shares for transaction amount of $1.77M was made by New Enterprise Associates 16, L.P. (10 percent owner) on 2024‑12‑23.

List of Insider Buy and Sell Transactions, Marker Therapeutics, Inc.

2024-12-23PurchaseNew Enterprise Associates 16, L.P.10 percent owner
554,250
5.7713%
$3.20
$1.77M
-63.30%
2024-12-23PurchaseELMS STEVEdirector
11,085
0.1154%
$3.20
$35,472
-63.30%
2021-05-18PurchaseWasserman Frederick Geralddirector
10,000
0.0119%
$2.41
$24,098
-43.03%
2021-03-16PurchaseWalker Paul Edward10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseSonsini Peter W.10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseSANDELL SCOTT D10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseNew Enterprise Associates 16, L.P.10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseMAKOWER JOSHUA10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseMakhzoumi Mohamad10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseFlorence Anthony A. Jr.10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseChang Carmen10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseBehbahani Ali10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseBASKETT FOREST10 percent owner
5.71M
9.5207%
$1.75
$10M
-4.30%
2021-03-16PurchaseWilson John Robertdirector
1.71M
2.8562%
$1.75
$3M
-4.30%
2021-03-16PurchaseELMS STEVEdirector
1.14M
1.9041%
$1.75
$2M
-4.30%
2021-03-16PurchaseVera JuanChief Development Officer
571,428
0.9521%
$1.75
$999,999
-4.30%
2021-03-16PurchaseHoang Peter L.President and CEO
142,857
0.238%
$1.75
$250,000
-4.30%
2021-03-16PurchaseEansor Norman Daviddirector
14,285
0.238%
$17.50
$249,988
-4.30%
2019-08-14PurchaseHoang Peter L.President and CEO
10,000
0.0219%
$4.62
$46,200
-41.13%
2018-05-14PurchaseEastern Capital LTD10 percent owner
2.6M
17.57%
$2.40
$6.24M
+127.00%
Total: 21

Insider Historical Profitability

<0.0001%
MAKOWER JOSHUA10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
SANDELL SCOTT D10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
BASKETT FOREST10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Walker Paul Edward10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Sonsini Peter W.10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Florence Anthony A. Jr.10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Behbahani Ali10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Makhzoumi Mohamad10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Chang Carmen10 percent owner
10714285
64.2609%
$12.64M10
<0.0001%
Wilson John Robertdirector
7799350
46.778%
$9.2M10
<0.0001%
Eastern Capital LTD10 percent owner
5300002
31.7877%
$6.25M10
+127%
Vera JuanChief Development Officer
2564487
15.381%
$3.03M10
<0.0001%
New Enterprise Associates 16, L.P.10 percent owner
1625678
9.7503%
$1.92M20
<0.0001%
Hoang Peter L.President and CEO
332568
1.9946%
$392,430.2420
<0.0001%
ELMS STEVEdirector
325370
1.9515%
$383,936.6020
<0.0001%
CORIN DENISPresident and CFO
135300
0.8115%
$159,654.0001
Wasserman Frederick Geralddirector
52565
0.3153%
$62,026.7010
<0.0001%
Eansor Norman Daviddirector
16713
0.1002%
$19,721.3410
<0.0001%

Historical Insider Profitability vs. Competitors

$1,993,425
46
-21.90%
$16.08M
$95,344,010
36
-18.97%
$14.94M
$30,257,839
29
-15.72%
$23.91M
$555,628
21
43.52%
$20.2M
Marker Therapeutics, Inc.
(MRKR)
$114,619,342
20
-7.41%
$19.67M
$742,412
14
-50.36%
$19.38M
$365,792
12
-15.77%
$18.94M
$1,246,170
12
65.67%
$20.72M
$4,146,041
11
-40.86%
$16.68M
$176,752
10
-28.86%
$23.38M
$4,176,565
9
18.77%
$22.6M
$8,971,546
8
6.18%
$19.9M
$654,995
7
-60.00%
$20.68M
$5,117,729
6
-52.29%
$16.46M
$2,060,158
5
-21.35%
$15.58M
$1,124,966
4
0.87%
$18.96M
$150,000
1
5.48%
$24.31M
$35,811
1
-10.94%
$23.7M
$30,190
1
-42.39%
$15.03M

MRKR Institutional Investors: Active Positions

Increased Positions19+59.38%728,901+20.88%
Decreased Positions9-28.13%175,237-5.02%
New Positions9New312,083New
Sold Out Positions6Sold Out163,521Sold Out
Total Postitions42+31.25%4M+15.86%

MRKR Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Nea Management Company, Llc$2,504.009.56%1.63M00%2025-09-30
Blue Owl Capital Holdings Lp$854.003.26%554,25000%2025-09-30
Aisling Capital Management Lp$501.001.91%325,37000%2025-09-30
Vanguard Group Inc$462.001.76%299,781+24,436+8.88%2025-09-30
Renaissance Technologies Llc$164.000.63%106,250+36,808+53.01%2025-09-30
Geode Capital Management, Llc$148.000.57%96,316+548+0.57%2025-09-30
Osaic Holdings, Inc.$125.000.48%81,081+61,504+314.17%2025-09-30
Lpl Financial Llc$90.000.35%58,747-15,000-20.34%2025-09-30
Torrey Growth & Income Advisors$80.000.31%51,984+51,984New2025-09-30
Two Sigma Securities, Llc$73.000.28%47,603+47,603New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.